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Abstract
Henoch-Schönlein purpura is one of the most common forms of systemic vasculitis of childhood. We report the
response to anakinra, the interleukin-1 receptor antagonist, in a 9 year old girl without prior medical problems who
developed life-threatening Henoch-Schönlein vasculitis that produced renal failure, pulmonary hemorrhage and
vasculitis of the brain. Her response supports the theory that interleukin-1 may be an important mediator in this
disease. Further study of interleukin-1 antagonists in severe Henoch-Schönlein purpura may be warranted.
Background
Henoch-Schönlein purpura (HSP) is the most common
form of childhood vasculitis [1-8] affecting 10-20 per
100,000 children annually [1-3,5]. It occurs most fre-
quently in children between the ages of 2 and 11 years [1].
HSP produces a broad array of clinical features resulting
from widespread IgA deposition in the walls of small ves-
sels [3]. Purpura of the skin, joint pain and swelling, gas-
trointestinal symptoms, and renal involvement are the
most common manifestations with frequencies of 100%
[2,3,9], 75% [2,3,8], 50-75%, and 40-50% [1-8] of the
patient population, respectively. Less often, neurologic
complications, pulmonary hemorrhage, and testicular
vasculitis may occur [1-3]. Of these, glomerulonephritis
remains the strongest indicator of poor prognosis [1,6,8].
Most series show that 1-7% of children with HSP glomeru-
lonephritis will develop chronic renal failure [10-12].
Although reports describe the use of oral and parenteral
corticosteroids, pulse methylprednisolone, dapsone,
azathioprine, cyclophosphamide, cyclosporine, and plasma-
pheresis, researchers still lack strong evidence that con-
firms the superiority of any treatment regime in preventing
tissue damage [4-6,13-15]. A recent metanalysis supports
the use of glucocorticoids during acute disease, however
[5].
Henoch-Schönlein purpura is typically a benign and
self-limited systemic vasculitis. Perhaps because it does
not frequently cause permanent damage, its pathogenesis
remains relatively poorly understood. IgA deposition in
vessel walls is a consistent pathologic finding, and is the
hallmark of the disease [3]. The triggers that promote the
IgA production and tissue deposition, those that deter-
mine why some individuals get the disease while most do
not, and those that dictate why the disease can be life-
threatening in a minority of affected children are not
known.
A variety of therapeutic agents that target specific inflam-
matory cytokines are available for the treatment of rheu-
matic diseases. Biologic agents including soluble receptors
and monoclonal antibodies that block the action of a vari-
ety of cytokines including tumor necrosis alpha, interleu-
kin-1, interleukin-6 have been used with variable success in
Kawasaki disease[16-19], granulomatosis with polyangiitis
(Wegener granulomatosis) [20,21] and other severe forms
of vasculitis [22-28]. Experimental evidence suggests
inflammatory cytokines such as IL-1, TNF and IL-6 are
involved in the pathogenesis of HSP [29]. Reports over the
last 3 decades suggest that autoinflammatory diseases char-
acterized by high interleukin-1 production such as familial
Mediterranean fever may be associated with an increased
incidence of HSP, and with more severe disease [7,30-39],
making IL-1 an potential target in refractory disease.
Lead by data supporting an important role for IL-1 in
HSP pathogenesis, we present a case that may indicate a
direction for future research into novel therapies for severe
Henoch-Schönlein purpura.
Case Report
A 9 year old girl presented with a one week history of
abdominal pain, vomiting, swelling and pain of the left
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tocks and lower extremities, consistent with a diagnosis
of Henoch-Schönlein purpura nephritis. Her initial
serum creatinine was normal at 0.5 mg/dL, but she had
hypoalbuminemia (serum albumin was 2.7 mg/dL) and
high grade proteinuria with urine protein:creatinine
ratio of 15.1. After a three day course of 2 mg/kg/day
methylprednisolone, her abdominal pain and rash
improved. She was discharged on 2 mg/kg/day oral pre-
dnisone with plans to follow-up with her nephrologist in
two weeks. Within a week, her HSP rash, abdominal
pain and arthralgia returned, so she was admitted again
to the hospital (see time course of her illness and treat-
ment in Figure 1). She had nephrotic range proteinuria
with a fall in serum albumin from 2.7 to 1.2 g/dL. Her
serum creatinine had risen to 1.7 mg/dL, with blood urea
nitrogen of 55 mg/dL. A kidney biopsy revealed crescents
in more than half of the glomeruli, with sclerosing lesions
and abundant IgA deposits indicative of severe HSPN.
She received a three day course of 30 mg/kg/day methyl-
prednisolone and began mycophenolate mofetil but failed
to improve, with progressive rise in serum creatinine
over four days to 2.5 mg/dL.
At the time she was readmitted, she had mild dyspnea
and hypoxemia. Despite vigorous diuresis and broad
spectrum antimicrobial coverage, her condition pro-
gressed to respiratory failure by the second week. Chest
radiography showed diffuse patchy infiltrates (Figure 2).
Bronchoalveolar lavage confirmed pulmonary hemor-
rhage grossly, with fresh blood and hemosiderin laden
macrophages identified in the lavage fluid. Because of
the child’s rising creatinine and lack of response to
more conventional treatments, she received IVIG ther-
apy and a 2 week course of plasmapheresis, but had lit-
tle clinical response. After a week of plasmapheresis she
developed initially focal, then generalized seizures and
required anticonvulsant therapy. She had altered mental
status with sluggish cognition. MRI of the brain showed
Figure 1 Timeline of Response to Therapy. Time in weeks after the onset of first symptoms of HSP is shown on the horizontal axis. The
vertical axis shows serum creatinine in mg/dl (red), and therapeutic measures used. The daily dose of glucocorticoid in mg/kg/day is in blue;
methylprednisolone pulse therapy is represented by blue arrows (30 mg/kg/day for 5 days, each arrow); and in the upper portion of the figure,
anakinra dose is illustrated. Note that the serum creatinine rose when the anakinra dose was decreased, both at week eleven and at week thirty.
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cerebral vasculitis (Figure 3). The pattern of edema was
not suggestive of posterior reversible encephalopathy
syndrome secondary to hypertension. By this time, the
serum creatinine was 4.8 mg/dL.
Based on evidence that severe HSP may be character-
ized by interleukin-1 (IL-1) over-production [7,34,40], a
planned one-day trial of anakinra (recombinant IL-1
receptor antagonist) was initiated in the hopes of avoid-
ing the toxicity of cyclophosphamide therapy. Accord-
ingly, her renal function rapidly improved and serum
creatinine fell from 4.8 mg/d to 2.4 in 48 hours, and
further to 1.0 in 10 days. Both neurologic and pulmon-
ary dysfunction cleared rapidly, and she was weaned
from ventilator within 24 hours. Anakinra was contin-
ued daily for 6 weeks, and then it was discontinued,
because the child objected strongly to the injections, her
serum creatinine was stable at 0.8 mg/dL, and it was
Figure 2 Chest X-ray showing pulmonary hemorrhage.D i f f u s e
alveolar opacification is apparent, particularly in the right upper
lobe. Bronchoalveolar lavage revealed fresh blood and hemosiderin
laden macrophages.
Figure 3 Brain Magnetic Resonance Imaging. These two coronal FLAIR images demonstrate increased signal intensity within the cortical gray
matter of the parietal, occipital and frontal lobes, with minimal involvement of the sub-cortical white matter. The deep white matter is spared.
This picture is consistent with scattered regions of vasogenic edema most consistent with vasculitis, and not indicative of posterior reversible
encephalopathy from hypertension.
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improvement.
Within one week of stopping the anakinra, the serum
creatinine rose to 3.26 mg/dL despite continuous pre-
dnisone (1 mg/kg/day) and mycophenolate mofetil.
Renal biopsy at this time again showed active vasculitis
with evidence of progression with early interstitial fibro-
sis and tubular atrophy, as well as progression from cel-
lular to fibrous crescents, and global glomerulosclersosis
of 20% of glomeruli. Because of the rising creatinine and
biopsy findings, she resumed daily anakinra at twice her
previous dose (100 mg/day) and received another course
of plasmapheresis. She had persistent hypertension dur-
ing this period requiring a variety of medications. After
resuming anakinra, her renal function and hypertension
improved and remained stable with serum creatinine
between 1.0 and 1.8 mg/dL (higher levels with lower
prednisone doses).
Four months after resuming anakinra, an attempt was
made to wean the injections to every other day. The crea-
tinine rose from 1.8 to 2.5 mg/dL within two weeks, so
she returned to daily dosing (100 mg/day). Unfortunately,
her renal function improved only transiently, and her
creatinine again rose. Her glomerulonephritis was unre-
sponsive to higher doses of glucocorticoid, and renal fail-
ure ensued. Eleven months after her initial diagnosis, a
renal biopsy was performed to determine whether further
aggressive immunosuppression was warranted. This
biopsy revealed global glomerulosclerosis involving
nearly 100% of the glomeruli and marked interstitial
fibrosis with tubular atrophy. She began dialysis two
weeks later. Fourteen months after her initial diagnosis,
she received a successful renal transplant.
Discussion
In the child described in this report with life-threatening
systemic vasculitis that caused renal failure, pulmonary
hemorrhage and diffuse vasculitis of the brain with sei-
zures and impaired cognition, there was no prior medical
history to suggest an underlying autoinflammatory condi-
tion characterized by over-production of interleukin-1. In
fact, subsequent DNA analysis was negative for the com-
mon familial Mediterranean fever gene mutations. The
severe HSP complications occurred despite plasmapher-
esis, pulse methylprednisolone and high dose mycophe-
nolate mofetil. In an attempt to avoid the toxicity of
cyclophosphamide [41-43], a one-day trial of subcuta-
neous anakinra was undertaken with rapid and dramatic
improvement. The HSP relapsed twice when the anakinra
was tapered, and she improved with reinstitution of the
drug. Unfortunately, the disease ultimately progressed to
irreversible renal failure. Thus in retrospect, either the
dose of anakinra should not have been decreased, or
cyclophosphamide might have proved a wiser choice of
treatment.
Conclusions
Although this single case report does not provide suffi-
cient evidence to indicate that treatment with an inter-
leukin-1 antagonist is either effective or safe in severe
HSP, it does suggest that disease may be ameliorated
with anakinra, and moreover, that further study of the
r o l eo fi n t e r l e u k i n - 1i nH S Pa n do fI L - 1a n t a g o n i s mi n
severe disease might be appropriate.
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